

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 64

January 24, 2022

ISSUE No.  
**1642**

### IN THIS ISSUE

*Paxlovid* for Treatment of COVID-19.....p 9

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 64 (Issue 1642)

January 24, 2022

Take CME Exams

### ▶ **Paxlovid for Treatment of COVID-19**

On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (*Paxlovid* – Pfizer) for oral treatment of mild to moderate COVID-19 in outpatients  $\geq 12$  years old who weigh at least 40 kg and are at high risk of progressing to severe disease, including hospitalization or death (see Table 1).<sup>1</sup> *Paxlovid* was the first oral antiviral drug to be authorized in the US for treatment of COVID-19; Merck's oral antiviral drug molnupiravir was granted an EUA for treatment of COVID-19 on December 23, 2021 (see page 10).<sup>2</sup> The IV antiviral drug remdesivir (*Veklury*) was approved by the FDA in 2020 for treatment of COVID-19 in hospitalized patients.<sup>3</sup>

**MECHANISM OF ACTION** – Nirmatrelvir inhibits the SARS-CoV-2 main protease (Mpro), preventing viral replication. Ritonavir does not have any activity against SARS-CoV-2, but it increases serum concentrations of nirmatrelvir by inhibiting its metabolism by CYP3A.

**CLINICAL STUDIES** – Issuance of the EUA for nirmatrelvir/ritonavir was based on the results of a randomized, double-blind, placebo-controlled trial (EPIC-HR) in 2246 nonhospitalized, unvaccinated adults with laboratory-confirmed SARS-CoV-2 infection, symptom onset within 5 days of randomization, and at least one risk factor associated with progression to severe disease. Nirmatrelvir 300 mg/ritonavir 100 mg twice daily for 5 days decreased COVID-19 related hospitalization or death through day 28 by 88% compared to placebo (0.8% vs 6.3%). There were 12 deaths in the placebo group versus none in the nirmatrelvir/ritonavir group. Delta was the primary SARS-CoV-2 variant in both groups.<sup>1</sup>

**ADVERSE EFFECTS** – The most common adverse effects of nirmatrelvir/ritonavir in EPIC-HR were dysgeusia, diarrhea, hypertension, and myalgia.

Table 1. Some High-Risk Conditions for COVID-19 Progression<sup>1</sup>

- ▶ Age  $\geq 65$  years
- ▶ BMI  $\geq 25$  kg/m<sup>2</sup> (or, in patients 12-17 years old, BMI  $\geq 85$ th percentile for age and gender<sup>2</sup>)
- ▶ Pregnancy or recent pregnancy
- ▶ Chronic kidney disease
- ▶ Chronic liver disease
- ▶ Current or former smoker or substance use disorder
- ▶ Malignancy
- ▶ Tuberculosis
- ▶ Down syndrome
- ▶ Diabetes
- ▶ Cardiovascular disease
- ▶ Hypertension
- ▶ COPD, moderate to severe asthma, or other chronic respiratory disease
- ▶ Immunosuppressive disease or currently receiving immunosuppressive treatment
- ▶ Sickle cell disease or thalassemia
- ▶ Congenital or acquired heart disease
- ▶ Dementia, neurodevelopmental disorders (e.g., cerebral palsy) or other conditions that confer medical complexity
- ▶ A medical-related technological dependence (e.g., tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])

BMI = body mass index; COPD = chronic obstructive pulmonary disease  
1. Adult and pediatric patients ( $\geq 12$  years old and weighing  $\geq 40$  kg) with  $\geq 1$  of the criteria listed are considered at high risk for progressing to severe COVID-19 or hospitalization. Available at: <https://bit.ly/3JILJD2>. Accessed January 6, 2022.  
2. Based on CDC growth charts. Available at: <https://bit.ly/36U0twf>. Accessed January 6, 2022.

**DRUG INTERACTIONS** – Both nirmatrelvir and ritonavir are CYP3A substrates; drugs that induce or inhibit CYP3A will affect serum concentrations of both drugs. Concurrent use of *Paxlovid* and strong CYP3A inducers, such as rifampin, carbamazepine, phenobarbital, phenytoin, or St. John's wort, can decrease serum concentrations of nirmatrelvir and ritonavir and is contraindicated.<sup>4</sup>

Ritonavir is a strong inhibitor of CYP3A and may increase serum concentrations of drugs metabolized by CYP3A. *Paxlovid* is contraindicated for use with drugs that are highly dependent on CYP3A for clearance and for which elevated serum concentrations are associated with serious or life-threatening events (e.g., amiodarone, midazolam). Recommendations for concomitant use of other CYP3A substrates are listed in the FDA Fact Sheet.<sup>1</sup>

Ritonavir decreases serum concentrations of ethinyl estradiol and may reduce the efficacy of combination hormonal contraceptives.

**PREGNANCY AND LACTATION** — There are no data on the use of nirmatrelvir in pregnant women. In animal studies, the drug was associated with reduced fetal weight, but no other adverse effects were detected. Observational data from the antiretroviral pregnancy registry did not show an increase in birth defects following use of ritonavir during pregnancies resulting in more than 6900 live births.

Ritonavir is secreted into human breast milk. No data are available on the presence of nirmatrelvir in human breast milk or the effects of either drug on the breastfed infant or milk production.

**VARIANTS** — Nirmatrelvir retains activity against the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants. According to the manufacturer, nirmatrelvir also inhibited the 3CL protease associated with the Omicron (B.1.1.529) variant in a biochemical assay.

**DOSAGE AND ADMINISTRATION** — *Paxlovid* is supplied in cartons containing nirmatrelvir 150-mg tablets copackaged with ritonavir 100-mg tablets. The recommended dosage is 300/100 mg (2 nirmatrelvir tablets and 1 ritonavir tablet taken together) twice daily for 5 days. Treatment should be started within 5 days of symptom onset. If a dose is missed by more than 8 hours, it should be skipped and

the next dose should be taken at the regularly scheduled time. In patients with moderate renal impairment (eGFR  $\geq$ 30 to  $<$ 60 mL/min), the dosage should be reduced to nirmatrelvir 150 mg/ritonavir 100 mg twice daily. *Paxlovid* is not recommended for use in patients with severe renal impairment (eGFR  $<$ 30 mL/min) or severe hepatic impairment (Child-Pugh C).

**CONCLUSION** — *Paxlovid*, the investigational oral antiviral drug nirmatrelvir copackaged with oral ritonavir, has received an Emergency Use Authorization from the FDA for treatment of mild to moderate COVID-19 in outpatients  $\geq$ 12 years old at high risk of progression to severe disease. In one trial, the antiviral combination decreased COVID-19 related hospitalization or death by 88%. It should be started as soon as possible after diagnosis and within 5 days of symptom onset. *Paxlovid* appears to be well tolerated, but ritonavir is a strong inhibitor of CYP3A and interacts with many other drugs. ■

1. FDA. Fact sheet for health care providers: Emergency Use Authorization for Paxlovid. December 22, 2021. Available at: <https://bit.ly/3sTNGqh>. Accessed January 6, 2022.
2. FDA. Fact sheet for health care providers: Emergency Use Authorization for molnupiravir. December 23, 2021. Available at: <https://bit.ly/3FSVSe2>. Accessed January 6, 2022.
3. Remdesivir (Veklury) for Covid-19. *Med Lett Drugs Ther* 2020; 62:186.
4. Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. *Med Lett Drugs Ther* 2021 October 20 (epub). Available at: [medicalletter.org/downloads/CYP\\_PGP\\_Tables.pdf](http://medicalletter.org/downloads/CYP_PGP_Tables.pdf).

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**VICE PRESIDENT AND EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
[www.medicalletter.org](http://www.medicalletter.org)

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**  
To reproduce any portion of this issue, please e-mail your request to: [permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**  
1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

**Site License Inquiries:**  
E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:  

Copyright 2022. ISSN 1523-2859

The  
Medical  
Letter